CYFUSE BIOMEDICAL K.K. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 729 JPY | +1.67% |
|
+3.26% | -4.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 374M 2.4M 201M | Sales 2023 | 61M 392K 32.7M | Capitalization | 5.96B 38.3M 3.19B |
|---|---|---|---|---|---|
| Net income 2022 | -473M -3.04M -254M | Net income 2023 | -589M -3.79M -316M | EV / Sales 2022 | 16.1 x |
| Net cash position 2022 | 3.53B 22.69M 1.89B | Net cash position 2023 | 2.96B 19.03M 1.59B | EV / Sales 2023 | 49.1 x |
| P/E ratio 2022 |
-7.34
x | P/E ratio 2023 |
-10.1
x | Employees | 21 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 62.74% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.67% | ||
| 1 week | +3.26% | ||
| Current month | +3.26% | ||
| 1 month | +1.67% | ||
| 3 months | +2.82% | ||
| 6 months | +0.14% | ||
| Current year | -4.33% |
1 week
702.00
735.00
1 month
673.00735.00
Current year
647.00869.00
1 year
647.001 270.00
3 years
647.002 468.00
5 years
647.002 468.00
10 years
647.002 468.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shizuka Akieda
CEO | Chief Executive Officer | - | - |
Masahiro Sanjo
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takuo Hirose
BRD | Director/Board Member | 52 | - |
Kunihiko Suzuki
BRD | Director/Board Member | 65 | - |
Shizuka Akieda
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 729 | +1.67% | 56 100 |
| 08/24/08 | 717 | +1.41% | 22,600 |
| 07/24/07 | 707 | +0.14% | 21,400 |
| 02/24/02 | 706 | +0.86% | 12,500 |
| 01/24/01 | 700 | -0.85% | 15,500 |
Delayed Quote Japan Exchange, May 09, 2024 at 11:30 am IST
More quotes
Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
Calendar
15/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -4.33% | 36.38M | |
| +24.80% | 46.71B | |
| +48.83% | 41.8B | |
| -1.12% | 41.52B | |
| -3.42% | 29.55B | |
| +10.49% | 25.78B | |
| -20.54% | 19.26B | |
| +0.69% | 12.14B | |
| -0.01% | 12.08B | |
| +26.07% | 11.98B |
- Stock Market
- Equities
- 4892 Stock